Dinesh P. de Alwis

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford et al. · Clinical Cancer Research · 2018 · 302 citations · Full text

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

L. Buéno, Dinesh P. de Alwis, Celine Pitou et al. · European Journal of Cancer · 2007 · 202 citations

Molecular Pharmacology, Semi-mechanistic Modelling, New Type +10

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 158 citations · Full text

Medicine, Pembrolizumab Dosing, Immune Checkpoint Inhibitor +6

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 154 citations

Six-weekly Dosing Schedule, Medicine, Cancer Management +6